Ford Motor Company

About: Ford Motor Company is a company organization based out in Dearborn, Michigan, United States. It is known for research contribution in the topics: Internal combustion engine & Clutch. The organization has 36123 authors who have published 51450 publications receiving 855200 citations. The organization is also known as: Ford Motor & Ford Motor Corporation.

Criterion for Ferromagnetism from Observations of Magnetic Isotherms

Abstract: A criterion is proposed for determining the onset of ferromagnetism in a material as its temperature is lowered from a region in which the linearity of its magnetic moment versus field isotherm gives an indication of paramagnetism. Within the limits of validity of a molecular field treatment, the Curie temperature is shown to be in general indicated by the third power of the magnetization being proportional to the internal magnetic field. The method has been employed to redetermine the Curie point of nickel from the data of Weiss and Forrer, of ${\mathrm{Fe}}_{3}$${\mathrm{O}}_{4}$ from the data of Smith and of some alloys from the data of Kaufmann and his collaborators and the author.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Abstract: A B S T R AC T BACKGROUND Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection. METHODS We conducted two randomized, phase 3 studies involving patients with chronic HCV genotype 2 or 3 infection. In one trial, patients for whom treatment with peg­ interferon was not an option received oral sofosbuvir and ribavirin (207 patients) or matching placebo (71) for 12 weeks. In a second trial, patients who had not had a response to prior interferon therapy received sofosbuvir and ribavirin for 12 weeks (103 patients) or 16 weeks (98). The primary end point was a sustained virologic response at 12 weeks after therapy. RESULTS Among patients for whom treatment with peginterferon was not an option, the rate of a sustained virologic response was 78% (95% confidence interval [CI], 72 to 83) with sofosbuvir and ribavirin, as compared with 0% with placebo (P<0.001). Among previously treated patients, the rate of response was 50% with 12 weeks of treat­ ment, as compared with 73% with 16 weeks of treatment (difference, −23 percent ­ age points; 95% CI, −35 to −11; P<0.001). In both studies, response rates were lower among patients with genotype 3 infection than among those with genotype 2 infection and, among patients with genotype 3 infection, lower among those with cirrhosis than among those without cirrhosis. The most common adverse events were headache, fatigue, nausea, and insomnia; the overall rate of discontinuation of sofosbuvir was low (1 to 2%). CONCLUSIONS In patients with HCV genotype 2 or 3 infection for whom treatment with peginter­ feron and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbu­ vir and ribavirin was effective. Efficacy was increased among patients with HCV genotype 2 infection and those without cirrhosis. In previously treated patients with genotype 3 infection, 16 weeks of therapy was significantly more effective than 12 weeks. (Funded by Gilead Sciences; POSITRON and FUSION ClinicalTrials.gov numbers, NCT01542788 and NCT01604850, respectively.)

The direct examination of three‐dimensional bone architecture in vitro by computed tomography

Abstract: We describe a new method for the direct examination of three-dimensional bone structure in vitro based on high-resolution computed tomography (CT). Unlike clinical CT, a three-dimensional reconstruction array is created directly, rather than a series of two-dimensional slices. All structural indices commonly determined from two-dimensional histologic sections can be obtained nondestructively from a large number of slices in each of three orthogonal directions. This permits a comprehensive description of structural variation within a specimen and greatly facilitates the study of structural anisotropy. A measure of three-dimensional connectivity (Euler number/tissue volume) has been determined for the first time in human cancellous bone and shown to correlate with several two-dimensional histomorphometric indices. The method has the potential for overcoming many of the limitations of current approaches to the study of bone architecture at the microscopic level.

Predictive energy management of a power-split hybrid electric vehicle

Abstract: In this paper, a Model Predictive Control (MPC) strategy is developed for the first time to solve the optimal energy management problem of power-split hybrid electric vehicles. A power-split hybrid combines the advantages of series and parallel hybrids by utilizing two electric machines and a combustion engine. Because of its many modes of operation, modeling a power-split configuration is complex and devising a near-optimal power management strategy is quite challenging. To systematically improve the fuel economy of a power-split hybrid, we formulate the power management problem as a nonlinear optimization problem. The nonlinear powertrain model and the constraints are linearized at each sample time and a receding horizon linear MPC strategy is employed to determine the power split ratio based on the updated model. Simulation results over multiple driving cycles indicate better fuel economy over conventional strategies can be achieved. In addition the proposed algorithm is causal and has the potential for real-time implementation.

Effect of nesiritide in patients with acute decompensated heart failure.

Abstract: A b s t r ac t Background Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. Methods We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. Results Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P = 0.03) and 24 hours (68.2% vs. 66.1%, P = 0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, −0.7 percentage points; 95% confidence interval [CI], −2.1 to 0.7; P = 0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, −0.4 percentage points; 95% CI, −1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P = 0.11). Conclusions Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.)